Ten Strategies For Success In Antibody-Drug Conjugate Development
Executive Summary
The future looks rosy after a slow start for antibody-drug conjugates. But what are the best tactics to capture a slice of the growing opportunity?
You may also be interested in...
Late To The Antibody-Drug Conjugate Party, But Will 2024 Be A Turning Point For India?
In 2024, Sun Pharma’s ADC candidate is expected to be in human trials, while CDMOs like Piramal Pharma Solutions and Aurigene are to operationalize significant new capacities. But can India compensate for a late start on the ADC journey by tapping low development costs and favorable policies, or is it too little with China far ahead in the race?
ImmunoGen Transitions To Commercial Stage With Elahere Launch
The antibody-drug conjugate was approved by the US FDA for the treatment of FRα-positive, platinum-resistant epithelial ovarian cancer.
Innate Pursues Anti-Leukemic In EU
Innate Pharma pursues refractory hairy cell leukemia opportunity with first-in-class CD22-directed immunotoxin, moxetumomab pasudotox-tdfk.